Currently Enrolling Trials
A highly selective SSRI, Celexa is the best-selling antidepressant in 13 countries, including eight in Europe.
Celexa has been proven effective and well tolerated in clinical trials involving more than 23,000 Celexa-treated patients, as well as by a decade of clinical use during which more than eight million people in 64 countries have been treated with Celexa. Results from these trials show that Celexa consistently and significantly improves symptoms of depression, regardless of patient age, race or gender. In addition, studies have also shown that Celexa is significantly more effective than placebo in preventing relapse of depression.
Side effects reported include nausea, dry mouth and sleepiness.
As with others SSRIs, Celexa should not be taken together with monoamine oxidase inhibitors.